Irinotecan 40mg
Product Overview | |
Generic Name | Irinotecan 40mg |
Brand Name(s) | Campto® (Pfizer), Irinotel® |
Form | Inj Vial |
Strength | 40 mg |
Therapeutic Class | Topoisomerase I inhibitor |
ATC Code | L01XX19 |
Manufacturing & Regulatory | |
Manufacturer | Multiple Firms |
Country | India |
GMP Compliance | WHO-GMP certified facility |
DMF/CEP | Unknown – request from mfg |
COFEPRIS | Registered – exact Clave pending |
Free Sale Certificate | Yes |
Logistics & Export | |
MOQ | 10 vials |
Shelf Life | 12-24 Months |
Storage | 2–8 °C, cool & dry |
Incoterms | Exworks, DDP, FOB |
Lead Time | 2 weeks |
Documentation | |
Certificate of Analysis (COA) | Manufacturer provides COA |
SDS | Available on request |
CTD Summary | Available upon purchase with fee |
Description
Indications & Usage: Antineoplastic agent in FOLFIRI regimens for metastatic colorectal cancer; causes diarrhea and neutropenia; blocks topoisomerase I preventing DNA replication. Used in FOLFIRI, second-line colorectal, other GI tumors; diarrhoea and myelosuppression risk.